Baxter InternationalNYSE: BAX

Baxter International Inc., a leading global medical technology company, has announced a quarterly cash dividend of $0.17 per share of common stock. This dividend will be paid on January 2, 2025, to shareholders who are on record as of November 29, 2024. The annual dividend rate is set at $0.68 per share, reflecting the company's new quarterly rate ahead of the sale of its Kidney Care business.

Baxter has announced third-quarter results that are better than anticipated. However, the company's gross and operating margins have decreased.

Baxter International (BAX) reported quarterly earnings of $0.80 per share, which is higher than the Zacks Consensus Estimate of $0.78 per share. This is an increase compared to earnings of $0.68 per share from the same period last year.

On Friday, Baxter International lowered its yearly profit expectations because its intravenous solutions plant was affected by a hurricane, causing its stock to drop by 3.3% in early trading.

Baxter International Inc. (NYSE:BAX) will hold its Q3 2024 Earnings Conference Call on November 8, 2024, at 8:30 AM ET. The call will feature company leaders, including Clare Trachtman, Joe Almeida, and Joel Grade, along with participants from various financial institutions. Attendees will be in listen-only mode until the question-and-answer portion begins.

BAX's results for the third quarter are expected to improve due to favorable pricing and the introduction of new products. On the other hand, supply chain problems may have increased costs during this period.

Assess Baxter's (BAX) anticipated performance for the quarter that ended in September 2024 by going beyond the usual Wall Street revenue and profit predictions. Instead, focus on some important metrics to gain a clearer understanding of the company's outlook.

Scott Baxter, the CEO of Kontoor Brands, appears on CNBC's 'The Exchange' to talk about the company's strong performance in the third quarter, its growth driven by marketing efforts, and other related topics.

On Thursday, Baxter, a company that makes medical devices, announced that it has resumed production on its busiest intravenous solutions manufacturing line at its North Carolina plant, which had been affected by flooding from a hurricane.